Biocept, Inc. (Nasdaq: BIOC) is proud to announce that its 1-for-30 reverse stock split became effective at 4:05 p.m. Eastern Time on May 16, 2023 and their common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023. This exciting news brings a bright future for the company and their investors, as their trading symbol remains “BIOC”.
The reverse stock split successfully combined and converted each 30 pre-split shares of common stock into a single issued and outstanding share of common stock. No fractional shares were issued to stockholders as a result, though each holder of record received a cash payment to make up for the lack of fractional shares.
Shareholders of record can now expect to receive information about their share ownership following the reverse stock split courtesy of the Company’s trusty transfer agent, Continental Stock Transfer & Trust. It’s never been easier to stay up to date on your investment!
Biocept is revolutionizing the way physicians diagnose and monitor cancer patients with carcinomas or melanomas. Our innovative, patented approach isolates cancer material that is shed from the primary tumor – such as CSF tumor cells and cell-free DNA – which can be rapidly detected and monitored from a cerebrospinal fluid sample.
With years of research and development in this area, Biocept has become a leading provider of testing services, empowering clinicians to quickly and accurately diagnose and monitor cancer patients.